146 Liver disease outcomes in people with cystic fibrosis after 2 years of elexacaftor/tezacaftor/ivacaftor—results from the RECOVER trialElizabeth Fitzpatrick, P. McNally, L. Kirwan et al.|Journal of Cystic Fibrosis|2024Cited by 0
P387 Ensuring Excellence: The Data Quality Programme of the cystic fibrosis Registry of IrelandL. Kirwan, R. Doherty, S. Joshy et al.|Journal of Cystic Fibrosis|2025Cited by 0
P386 Health outcomes for PwCF switching from a CFTR modulator therapy (CFTRm) to elexaftor/tezacaftor/ivacaftor (ETI) compared with those starting on ETI naively. A study using Irish registry dataP. O’Regan, L. Kirwan, S. Joshy et al.|Journal of Cystic Fibrosis|2025Cited by 0
WS19.03 Improvements in structural lung disease over 24 months in children with CF aged 6-11 on elexacaftor/tezacaftor/ivacaftor (ETI) – interim analysis using automated LungQ scoringP. McNally, H. Tiddens, K. Lester et al.|Journal of Cystic Fibrosis|2025Cited by 0